Cantoni Claudia, Grauwet Korneel, Pietra Gabriella, Parodi Monica, Mingari Maria Cristina, De Maria Andrea, Favoreel Herman, Vitale Massimo
Department of Experimental Medicine (DIMES), University of Genova, Genova, Italy.
Center of Excellence for Biomedical Research (CEBR), University of Genova, Genova, Italy.
Immunotherapy. 2015;7(8):861-82. doi: 10.2217/imt.15.53. Epub 2015 Aug 28.
Although natural killer (NK) cells are endowed with powerful cytolytic activity against cancer cells, their role in different therapies against solid tumors has not yet been fully elucidated. Their interactions with various elements of the tumor microenvironment as well as their possible effects in contributing to and/or limiting oncolytic virotherapy render this potential immunotherapeutic tool still difficult to exploit at the bedside. Here, we will review the current literature with the aim of providing new hints to manage this powerful cell type in future innovative therapies, such as the use of NK cells in combination with new cytokines, specific mAbs (inducing ADCC), Tyr-Kinase inhibitors, immunomodulatory drugs and/or the design of oncolytic viruses aimed at optimizing the effect of NK cells in virotherapy.
尽管自然杀伤（NK）细胞具有针对癌细胞的强大细胞溶解活性，但其在针对实体瘤的不同疗法中的作用尚未完全阐明。它们与肿瘤微环境的各种成分之间的相互作用，以及它们在促进和/或限制溶瘤病毒疗法方面可能产生的影响，使得这种潜在的免疫治疗工具在临床应用中仍难以充分利用。在此，我们将回顾当前的文献，旨在为在未来的创新疗法中管理这种强大的细胞类型提供新的线索，例如将NK细胞与新的细胞因子、特异性单克隆抗体（诱导抗体依赖性细胞介导的细胞毒性）、酪氨酸激酶抑制剂、免疫调节药物联合使用，和/或设计旨在优化NK细胞在病毒疗法中作用的溶瘤病毒。
